X4 Pharmaceuticals Announces Inducement Awards for New Employees
X4 Pharmaceuticals (Nasdaq: XFOR), a company dedicated to developing innovative therapies for rare immune system diseases, has recently revealed that it will issue inducement awards to its newly hired staff, effective August 30, 2024. This decision is part of the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan, which is specifically tailored for individuals who have not previously worked with the company.
Overview of the Inducement Awards
The inducement awards consist of options to acquire a total of 230,588 shares of X4’s common stock. These awards are a vital incentive for new employees to become part of the committed team at X4. The Compensation Committee of the Board of Directors approved this initiative in compliance with the Nasdaq Listing Rule 5635(c)(4).
Details on Option Terms and Vesting
These stock options feature a ten-year term with an exercise price of $0.70 per share, which is equal to the closing price on the date of the grant. The options will vest over a four-year period, allowing new employees to earn 25% of the shares after 12 months, with the remaining shares vesting monthly over the following 36 months, contingent upon their continued employment with the company.
About X4 Pharmaceuticals
X4 Pharmaceuticals is committed to improving the lives of patients affected by rare immune system diseases. The company utilizes its expertise in CXCR4 and immune biology to create new therapies. A significant achievement for X4 is the advancement of mavorixafor, which is marketed under the brand name XOLREMDI, representing a key milestone in their therapeutic portfolio. The company is also actively investigating additional indications for mavorixafor, highlighting its dedication to addressing significant unmet medical needs.
Company Locations and Research Initiatives
Headquartered in Boston, Massachusetts, X4 also has a research center of excellence in Vienna, Austria. This dual presence allows the company to attract top talent and promote innovation in drug development.
Contact Information
For inquiries regarding corporate and patient affairs, please reach out to José Juves, Head of Corporate & Patient Affairs, via email at jose.juves@x4pharma.com. For investor-related questions, Daniel Ferry, Managing Director at LifeSci Advisors, is available at daniel@lifesciadvisors.com or by phone at (617) 430-7576.
Frequently Asked Questions
What are the inducement awards issued by X4 Pharmaceuticals?
Inducement awards are stock options given to new employees to encourage them to join the company under specific corporate plans.
What is the exercise price of the options granted?
The exercise price for the options is $0.70 per share, which corresponds to the closing stock price on the grant date.
How long do the options last?
The options are valid for ten years, providing employees ample time to exercise them.
What is X4 Pharmaceuticals known for?
X4 Pharmaceuticals is recognized for its development of innovative therapies targeting rare diseases of the immune system, with mavorixafor being a prominent product.
Where is X4 Pharmaceuticals headquartered?
The company is headquartered in Boston, Massachusetts, and has a research facility located in Vienna, Austria.
